• H. Lundbeck A/S published an investor presentation on bocunebart, positioning PACAP inhibition as a new mechanism for severe migraine prevention alongside Vyepti.
• PROCEED Phase 2b met its primary endpoint for one IV dose, cutting monthly migraine days by 4.24 vs 2.86 for placebo over weeks 1-12.
• Other doses showed numerical reductions versus placebo but missed statistical significance; safety profile was generally well tolerated with no new signals flagged.
• Post-hoc pooled analysis in chronic migraine showed 5.9 fewer monthly migraine days with bocunebart vs 3.6 with placebo at week 12.
• Phase 3 planning is underway, with regulatory interactions cited; next program update is slated for 2H 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. H. Lundbeck A/S published the original content used to generate this news brief on June 05, 2026, and is solely responsible for the information contained therein.